Expert Interview
A Second Opinion: Discussing AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial data from ASCO 2023 in patients with HER2-expressing advanced solid tumors.
Ticker(s): AZN, DSKYFInstitution: Advanced Care Oncology And Hematology Associates
- Board certified in hematology and medical oncology, maintaining vibrant community office practices in Springfield and Morristown, NJ.
- Knowledgable of PI3 kinase inhibitors, novel CAR-T therapies, FGFR2 inhibitors, and other immuno-oncology therapeutics in development.
- Areas of interest include gastrointestinal and genitourinary malignancies, although he is trained in all malignancies and blood disorders.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
